Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Overview and Analysis
- The Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market vaccines is part of the larger swine vaccine market, which was valued at an estimated USD 1.58 billion in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 8.23% to reach USD 3.29 billion by 2032.
The Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market refers to the segment of the veterinary pharmaceutical industry focused on developing, producing, and distributing inactivated (killed) vaccines used to prevent Mycoplasma hyopneumoniae infections in pigs. This disease, a major cause of respiratory illness in swine, leads to reduced weight gain, poor feed efficiency, and significant economic losses in pork production. The market includes various vaccine formulations designed for safety, long-lasting immunity, and compatibility with other pig vaccines. Growth is driven by rising global pork demand, biosecurity awareness, and the need for herd health optimization. It involves veterinary healthcare providers, animal vaccine manufacturers, and commercial pig farms seeking disease control and improved productivity.
Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Latest Trends
The Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market is witnessing steady growth driven by increasing awareness among swine producers about herd health management and respiratory disease prevention. There is a growing preference for inactivated vaccines due to their safety profile, longer shelf life, and compatibility with other vaccine regimens. Technological advancements in vaccine formulation, including adjuvant optimization and intramuscular delivery systems, are enhancing immunogenicity and reducing administration stress on animals. Additionally, integrated health programs and government initiatives in key pork-producing countries are encouraging widespread vaccine adoption. The demand is also being supported by the intensification of pig farming, rising global pork consumption, and a shift towards preventative veterinary care in commercial operations.
Segmentation: The Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market is segmented by Vaccine Formulations (Monovalent and Polyvalent Vaccines), Administration Routes (Intramuscular and Subcutaneous Injections), End-Users (Commercial Pig Farms, Veterinary Hospitals & Clinics, and Smallholder or Backyard Pig Farmers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides the value (in USD million) for the above segments.
Market Drivers:
- Rising Prevalence of Swine Mycoplasma Pneumonia
The increasing incidence of respiratory diseases such as Mycoplasma pneumonia in swine herds globally drives demand for effective vaccination solutions. Swine pneumonia causes significant economic losses due to decreased growth rates, increased mortality, and treatment costs. Inactivated vaccines offer a reliable preventive approach, encouraging widespread adoption among pig farmers to maintain herd health and productivity.
Additionally, advancements in vaccine technology, including improved formulations and delivery methods, are enhancing the effectiveness and ease of use of inactivated vaccines for swine mycoplasma pneumonia. Growing awareness among farmers about biosecurity and animal welfare is further fueling market growth, as healthier herds translate to better meat quality and profitability. Government initiatives and support for disease control in livestock also contribute to increasing vaccine adoption, particularly in regions with large-scale commercial pig farming. These factors collectively create a strong market environment, driving continuous demand for innovative and effective swine pneumonia vaccines globally.
- Growing Swine Industry and Intensive Farming Practices
The expansion of commercial pig farming and adoption of intensive farming methods create favorable conditions for disease spread, necessitating preventive healthcare measures. Increasing consumer demand for pork products fuels swine production, which in turn boosts the need for vaccination to minimize disease outbreaks and ensure sustainable operations, supporting market growth.
Market Restraints:
- High Cost and Limited Accessibility in Developing Regions
The relatively high cost of inactivated vaccines and logistical challenges in distribution can limit their accessibility in low-income and remote farming areas. Small-scale farmers may face difficulties affording or obtaining vaccines, hindering market penetration and slowing overall growth, especially in developing countries where swine farming is fragmented and less organized.
Socio Economic Impact on Inactivated Vaccine for Swine Mycoplasma Pneumonia Market
The use of inactivated vaccines for swine mycoplasma pneumonia significantly reduces disease burden, improving animal welfare and productivity, which directly impacts food security and rural livelihoods. By preventing respiratory infections in pigs, these vaccines help lower the use of antibiotics, contributing to global antimicrobial resistance (AMR) control efforts. Economically, improved swine health leads to better feed efficiency, weight gain, and reduced mortality rates—translating into higher returns for pig farmers and greater pork supply for consumers. In developing countries, where small- to medium-scale swine farming supports millions of livelihoods, effective vaccination programs can uplift farm income and stimulate local veterinary service sectors, promoting broader rural development and public health outcomes.
Segmental Analysis:
- Monovalent segment is expected to witness highest growth over the forecast period
The monovalent segment is expected to witness the highest growth over the forecast period due to its targeted approach in preventing swine mycoplasma pneumonia. Monovalent vaccines specifically protect against Mycoplasma hyopneumoniae, offering more precise immunity with fewer side effects. This specificity appeals to commercial pig producers looking to enhance animal health while minimizing vaccine-related complications. Additionally, monovalent vaccines are often preferred in regions where co-infection rates with other pathogens are low, allowing for focused disease control. Increasing awareness about the benefits of targeted vaccination and rising demand for effective swine health management are key factors driving growth in this segment globally.
- Subcutaneous Injections segment is expected to witness highest growth over the forecast period
The subcutaneous injections segment is projected to experience the highest growth during the forecast period due to several advantages over other administration routes. Subcutaneous delivery is less invasive and causes reduced tissue damage, leading to better animal welfare and compliance. It also simplifies the vaccination process, especially in large-scale commercial farms, by enabling quicker and easier administration. Moreover, advancements in vaccine formulations optimized for subcutaneous use have improved immunogenicity and safety profiles, further driving adoption. As farmers and veterinarians increasingly prioritize efficient and humane vaccination methods, demand for subcutaneous inactivated vaccines against swine mycoplasma pneumonia is set to rise significantly.
- Commercial Pig Farms segment is expected to witness highest growth over the forecast period
The commercial pig farms segment is expected to see the highest growth over the forecast period, driven by the rising scale and industrialization of pork production globally. Large-scale farms prioritize disease prevention to reduce economic losses caused by swine respiratory illnesses like mycoplasma pneumonia. These farms often have the resources to invest in vaccination programs, including inactivated vaccines, to maintain herd health and productivity. Increasing pork consumption and export demands, particularly in Asia and North America, are also fueling farm expansion and intensifying the need for effective disease control measures. Consequently, commercial pig farms are becoming the largest consumers of swine mycoplasma vaccines, propelling market growth.
- North America region is expected to witness highest growth over the forecast period
The North America region is expected to witness the highest growth in the inactivated vaccine market for swine mycoplasma pneumonia over the forecast period due to its well-established pork industry and advanced veterinary healthcare infrastructure. The region's emphasis on biosecurity and disease control has led to widespread adoption of vaccination programs. Additionally, increasing government initiatives to support animal health and strict regulatory standards ensure the use of effective and safe vaccines. Technological advancements in vaccine development, combined with growing awareness among pig farmers about the economic benefits of disease prevention, are also driving market growth. North America's position as a major pork exporter further motivates the continuous enhancement of swine health management strategies.
Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Competitive Landscape
The market is moderately competitive, with several global and regional veterinary pharmaceutical companies offering inactivated swine mycoplasma pneumonia vaccines. Key players include Merck Animal Health, Boehringer Ingelheim, Zoetis, Ceva Santé Animale, and Elanco, who invest heavily in R&D, cold chain logistics, and veterinarian outreach. These firms compete on vaccine efficacy, product safety, dosage convenience, and integration with broader swine health programs. Meanwhile, emerging regional manufacturers are gaining ground in Asia and Latin America by offering cost-effective, locally-adapted solutions. Strategic partnerships, licensing agreements, and regulatory approvals play a vital role in expanding market access. As swine diseases evolve, innovation and global collaboration remain critical for maintaining market leadership.
The 20 major players for above market are:
- Merck Animal Health
- Zoetis Inc.
- Boehringer Ingelheim Animal Health
- Elanco Animal Health
- Ceva Santé Animale
- HIPRA
- Vetoquinol S.A.
- Virbac
- Phibro Animal Health Corporation
- Bayer Animal Health
- IDT Biologika GmbH
- KV Pharm
- Arko Laboratories Pvt. Ltd.
- Indian Immunologicals Ltd.
- Biovet Inc.
- Livestock Improvement Corporation (LIC)
- Sichuan Shineway Pharmaceutical Co., Ltd.
- Hebei Veyong Animal Pharmaceutical Co., Ltd.
- Jilin Saide Biology Pharmaceutical Co., Ltd.
- Guangdong Dahuanong Animal Health Products Co., Ltd.
Recent Development
- In February 2025, an article published in, Frontiers in Cellular and Infection Microbiology, reported that tudy evaluated the immune responses of three immunodominant proteins—rMhp170, rMhp274, and rMhp336—from Mycoplasma hyopneumoniae in BALB/c mice. Results showed that rMhp170 and rMhp274 induced strong systemic and mucosal immune responses, including IgG, sIgA, and key cytokines (IFN-γ, IL-4, IL-17), along with significant lymphocyte proliferation. In contrast, rMhp336 triggered a more limited immune response. None of the proteins caused adverse effects or lung lesions. These findings highlight the potential of rMhp170 and rMhp274 as promising candidates for more effective vaccines against mycoplasmal pneumonia in swine.
Frequently Asked Questions (FAQ) :
Q1. What the main growth driving factors for this market?
The market is primarily driven by the high prevalence and significant economic losses caused by Mycoplasma hyopneumoniae infections in swine herds globally. Increased awareness among producers about the necessity of herd health management, combined with the rising worldwide demand for pork, fuels the adoption of effective, preventative inactivated vaccines to enhance productivity.
Q2. What are the main restraining factors for this market?
Major restraints include the variable efficacy of current vaccines due to potential antigenic differences between the vaccine strain (often J-strain based) and circulating field strains. Furthermore, the high costs of vaccine development and manufacturing, coupled with stringent regulatory approval processes, can limit market growth and accessibility, especially in developing regions.
Q3. Which segment is expected to witness high growth?
The Piglets segment, based on application, is expected to witness the highest growth. Early-stage vaccination of piglets is critical for developing herd immunity and minimizing the severe economic impact of the disease later in the production cycle, making this application segment the dominant and fastest-growing area.
Q4. Who are the top major players for this market?
The market is dominated by global animal health leaders. The top major players include Zoetis, Boehringer Ingelheim International GmbH, Merck & Co., Inc. (MSD Animal Health), and Ceva Santé Animale. These companies compete through product efficacy, developing combination vaccines, and leveraging extensive global distribution networks.
Q5. Which country is the largest player?
The United States is the largest country player, and North America dominates the regional market in terms of revenue share. This is attributed to a highly advanced veterinary healthcare infrastructure, a robust swine industry that prioritizes advanced biosecurity, and the presence of major global pharmaceutical companies.
List of Figures
Figure 1: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue Breakdown (USD Billion, %) by Region, 2022 & 2029
Figure 2: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 1, 2022 & 2029
Figure 3: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 4: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 5: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 2, 2022 & 2029
Figure 6: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 7: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 8: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 9: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 10: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 3, 2022 & 2029
Figure 11: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 12: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 13: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 14: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 15: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value (USD Billion), by Region, 2022 & 2029
Figure 16: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 1, 2022 & 2029
Figure 17: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 18: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 19: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 2, 2022 & 2029
Figure 20: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 21: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 22: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 23: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 24: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 3, 2022 & 2029
Figure 25: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 26: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 27: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 28: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 29: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by U.S., 2018-2029
Figure 30: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Canada, 2018-2029
Figure 31: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 1, 2022 & 2029
Figure 32: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 33: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 34: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 2, 2022 & 2029
Figure 35: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 36: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 37: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 38: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 39: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 3, 2022 & 2029
Figure 40: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 41: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 42: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 43: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 44: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Brazil, 2018-2029
Figure 45: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Mexico, 2018-2029
Figure 46: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Rest of Latin America, 2018-2029
Figure 47: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 1, 2022 & 2029
Figure 48: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 49: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 50: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 2, 2022 & 2029
Figure 51: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 52: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 53: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 54: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 55: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 3, 2022 & 2029
Figure 56: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 57: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 58: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 59: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 60: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by U.K., 2018-2029
Figure 61: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Germany, 2018-2029
Figure 62: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by France, 2018-2029
Figure 63: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Italy, 2018-2029
Figure 64: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Spain, 2018-2029
Figure 65: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Russia, 2018-2029
Figure 66: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Rest of Europe, 2018-2029
Figure 67: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 1, 2022 & 2029
Figure 68: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 69: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 70: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 2, 2022 & 2029
Figure 71: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 72: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 73: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 74: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 75: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 3, 2022 & 2029
Figure 76: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 77: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 78: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 79: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 80: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by China, 2018-2029
Figure 81: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by India, 2018-2029
Figure 82: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Japan, 2018-2029
Figure 83: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Australia, 2018-2029
Figure 84: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Southeast Asia, 2018-2029
Figure 85: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Rest of Asia Pacific, 2018-2029
Figure 86: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 1, 2022 & 2029
Figure 87: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 88: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 89: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 2, 2022 & 2029
Figure 90: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 91: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 92: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 93: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 94: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Value Share (%), By Segment 3, 2022 & 2029
Figure 95: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 96: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 97: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 98: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Others, 2018-2029
Figure 99: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by GCC, 2018-2029
Figure 100: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by South Africa, 2018-2029
Figure 101: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast (USD Billion), by Rest of Middle East & Africa, 2018-2029
List of Tables
Table 1: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 2: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 3: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 4: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Region, 2018-2029
Table 5: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 6: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 7: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 8: North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 9: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 10: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 11: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 12: Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 13: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 14: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 15: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 16: Latin America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 17: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 18: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 19: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 20: Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 21: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 22: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 23: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 24: Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Research Process
Data Library Research are conducted by industry experts who offer insight on
industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager
and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Primary Research
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary Research
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size Estimation
Both, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
